摘要
目的:探究于早发冠心病心肌梗死治疗中采用瑞舒伐他汀与阿托伐他汀临床疗效差异。方法:随机抽取老年科室收治的早发冠心病急性心肌梗死患者为平行比对对象,共计68例,依据随机抽签划分两组,一组34例患者予以阿托伐他汀治疗,设为研究A组,一组34例患者予以瑞舒伐他汀治疗,设为研究B组。结果:治疗前两组患者各指标数据差异均衡(P>0.05),治疗后,两组患者各指标均显著改善(P<0.05);治疗后,研究B组各指标改善情况优于研究A组(P<0.05);研究A组患者4例患者继发心绞痛,研究B组患者3例患者继发心绞痛,组间差均衡(P>0.05)。结论:瑞舒伐他汀与阿托伐他汀于早发冠心病心肌梗死治疗中均具有良好导向,瑞舒伐他汀临床效果优于阿托伐他汀。
Objective:To investigate the difference of clinical efficacy between resuvarastatin and Atto in the treatment of myocardial infarction in patients with early coronary heart disease.Methods:68 patients with acute myocardial infarction of early coronary heart disease were randomly selected and divided into two groups according to the random drawing of lots.34 patients in one group were treated with Atto statins as study group A and 34 patients in group B were treated with resuvarastatin.Results:The data of the two groups were balanced before treatment(P>0.05).After treatment,the indexes of the two groups were significantly improved(P<0.05).After that,the improvement of each index in group B was better than that in group A(P<0.05),the secondary angina pectoris in group A was studied in 4 patients in group A,and the secondary angina pectoris in group B was studied in 3 patients,and the difference between groups was balanced(P>0.05).Conclusion:Resuvarastatin and Atto statins have good guidance in the treatment of myocardial infarction in patients with early coronary heart disease.The clinical effect of resuvarastatin is better than that of Atto statins.
作者
陈德生
符信萍
廖佳隆
CHEN De-sheng;FU Xin-ping;LIAO Jia-long(Ningdu County People’s Hospital,Ganzhou Jiangxi 342800,China)
出处
《药品评价》
CAS
2019年第21期58-59,共2页
Drug Evaluation
关键词
瑞舒伐他汀
阿托伐他汀
早发冠心病心肌梗死
Resuvastatin
Atto Vastatin
Early Coronary Heart Disease Myocardial Infarction
